263016-08-6

Basic information

• Product Name: ETHYL 2-(4-CHLOROPHENYL)-4-HYDROXY-1,3-THIAZOLE-5-CARBOXYLATE
• Synonyms: ETHYL 2-(4-CHLOROPHENYL)-4-HYDROXY-1,3-THIAZOLE-5-CARBOXYLATE;ETHYL 2-(4-CHLOROPHENYL)-4-HYDROXYTHIAZOLE-5-CARBOXYLATE
• CAS NO: 263016-08-6
• Molecular Formula: C₁₂H₁₀ClNO₃S
• Molecular Weight: 283.73
• Mol File: 263016-08-6.mol

Chemical Properties

• Melting Point: 137-139
• Boiling Point: 413°Cat760mmHg
• Flash Point: 203.6°C
• Appearance: /
• Density: 1.403g/cm³
• Vapor Pressure: 2.07E-07mmHg at 25°C
• Refractive Index: 1.614
• CAS DataBase Reference: ETHYL 2-(4-CHLOROPHENYL)-4-HYDROXY-1,3-THIAZOLE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-(4-CHLOROPHENYL)-4-HYDROXY-1,3-THIAZOLE-5-CARBOXYLATE(263016-08-6)
• EPA Substance Registry System: ETHYL 2-(4-CHLOROPHENYL)-4-HYDROXY-1,3-THIAZOLE-5-CARBOXYLATE(263016-08-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 263016-08-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 2-(4-CHLOROPHENYL)-4-HYDROXY-1,3-THIAZOLE-5-CARBOXYLATE is used as a pharmaceutical intermediate for the development of medications. Its unique chemical structure and potential pharmacological properties make it a valuable compound in the synthesis of new drugs.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, ETHYL 2-(4-CHLOROPHENYL)-4-HYDROXY-1,3-THIAZOLE-5-CARBOXYLATE serves as a key building block for the design and synthesis of novel therapeutic agents. Its structural features can be exploited to create new molecules with improved pharmacological profiles and therapeutic potential.
Used in Drug Discovery:
ETHYL 2-(4-CHLOROPHENYL)-4-HYDROXY-1,3-THIAZOLE-5-CARBOXYLATE is utilized in drug discovery processes to identify and optimize lead compounds with potential therapeutic applications. Its unique chemical properties can contribute to the development of innovative drugs for various diseases and conditions.

InChI:InChI=1/C12H10ClNO3S/c1-2-17-12(16)9-10(15)14-11(18-9)7-3-5-8(13)6-4-7/h3-6,15H,2H2,1H3

Upstream product

• 685-87-0 Diethyl 2-bromomalonate 
• 2521-24-6 4-chlorothiobenzamide 

Downstream Products

• 1445753-34-3 N'-acetyl-2-(4-chlorophenyl)-4-hydroxy-1,3-thiazole-5-carbohydrazide 
• 1445752-07-7 2-(4-chlorophenyl)-4-hydroxy-1,3-thiazole-5-carboxylic acid 
• 1445753-02-5 2-(4-chlorophenyl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1,3-thiazol-4-ol 
• 1445752-41-9 ethyl 2-(4-chlorophenyl)-4-{2-[(furan-2-ylmethyl)amino]ethoxy}-1,3-thiazole-5-carboxylate 
• 1445752-90-8 ethyl 2-(4-chlorophenyl)-4-(methoxymethoxy)-1,3-thiazole-5-carboxylate 
• 1445752-40-8 ethyl 4-(2-aminoethoxy)-2-(4-chlorophenyl)-1,3-thiazole-5-carboxylate 
• 1445752-39-5 ethyl 4-[(benzylcarbamoyl)oxy]-2-(4-chlorophenyl)-1,3-thiazole-5-carboxylate 

Relevant articles and documents

Discovery of Novel TRPM8 Blockers Suitable for the Treatment of Somatic and Ocular Painful Conditions: A Journey through p Kaand LogD Modulation

Transient receptor potential melastatin 8 (TRPM8) is crucially involved in pain modulation and perception, and TRPM8 antagonists have been proposed as potential therapeutic approaches for pain treatment. Previously, we developed two TRPM8 antagonists and proposed them as drug candidates for topical and systemic pain treatment. Here, we describe the design and synthesis of these two TRPM8 antagonists (27 and 45) and the rational approach of modulation/replacement of bioisosteric chemical groups, which allowed us to identify a combination of narrow ranges of pKa and LogD values that were crucial to ultimately optimize their potency and metabolic stability. Following the same approach, we then pursued the development of new TRPM8 antagonists suitable for the topical treatment of ocular painful conditions and identified two new compounds (51 and 59), N-alkoxy amide derivatives, that can permeate across ocular tissue and reduce the behavioral responses induced by the topical ocular menthol challenge in vivo.

TRPM8 ANTAGONISTS

The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders.

Trpm8 antagonists

The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula: Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, inflammatory conditions and urological disorders.